Your browser doesn't support javascript.
loading
Detection of busulfan adducts on proteins.
Acosta-Martin, Adelina E; Antinori, Paola; Uppugunduri, Chakradhara Rao S; Daali, Youssef; Ansari, Marc; Scherl, Alexander; Müller, Markus; Lescuyer, Pierre.
Afiliação
  • Acosta-Martin AE; Department of Human Protein Science, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
  • Antinori P; Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland.
  • Uppugunduri CRS; Department of Human Protein Science, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
  • Daali Y; Swiss Centre of Applied Human Toxicology, Geneva, Switzerland.
  • Ansari M; Onco-Hematology Unit, Department of Pediatrics, Geneva University Hospitals, Geneva, Switzerland.
  • Scherl A; Cansearch Research Laboratory, Geneva Medical University, Geneva, Switzerland.
  • Müller M; Division of Clinical Pharmacology and Toxicology, Geneva University Hospitals, Geneva, Switzerland.
  • Lescuyer P; Onco-Hematology Unit, Department of Pediatrics, Geneva University Hospitals, Geneva, Switzerland.
Rapid Commun Mass Spectrom ; 30(23): 2517-2528, 2016 Dec 15.
Article em En | MEDLINE | ID: mdl-27599297
ABSTRACT
RATIONALE Busulfan is a bifunctional alkyl sulfonate antineoplastic drug. This alkylating agent was described as forming covalent adducts on proteins. However, only limited data are available regarding the interaction of busulfan with proteins. Mass spectrometry and bioinformatics were used to identify busulfan adducts on human serum albumin and hemoglobin.

METHODS:

Albumin and hemoglobin were incubated with busulfan or control compounds, digested with trypsin and analyzed by liquid chromatography/tandem mass spectrometry (LC/MS/MS) on a Thermo Fisher LTQ Orbitrap Velos Pro. MS data were used to generate spectral libraries of non-modified peptides and an open modification search was performed to identify potential adduct mass shifts and possible modification sites. Results were confirmed by a second database search including identified mass shifts and by visual inspection of annotated tandem mass spectra of adduct-carrying peptides.

RESULTS:

Five structures of busulfan adducts were detected and a chemical structure could be attributed to four of them. Two were primary adducts corresponding to busulfan monoalkylation and alkylation of two amino acid residues by a single busulfan molecule. Two others corresponded to secondary adducts generated during sample processing. Adducts were mainly detected on Asp, Glu, and His residues. These findings were confirmed by subsequent database searches and experiments with synthetic peptides.

CONCLUSIONS:

The combination of in vitro incubation of proteins with the drug of interest or control compounds, high-resolution mass spectrometry, and open modification search allowed confirmation of the direct interaction of busulfan with proteins and characterization of the resulting adducts. Our results also showed that careful analysis of the data is required to detect experimental artifacts. Copyright © 2016 John Wiley & Sons, Ltd.

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies Idioma: En Ano de publicação: 2016 Tipo de documento: Article